Indeed, positive immunostaining for pAKT, pERK, PTEN and EGFRvIII has been reported to predict sensitivity to EGFR tyrosine kinase inhibitors in non-small-cell lung cancer and glioblastoma (Han et al, 2004; Mellinghoff et al, 2005). This evidence concerns the gene EGFR and glioblastoma.